Aligos Therapeutics Inc
General ticker "ALGS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $183.4M
Aligos Therapeutics Inc follows the US Stock Market performance with the rate: 1.4%.
Estimated limits based on current volatility of 6.9%: low 36.09$, high 41.41$
Factors to consider:
- Current price 78.6% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [7.94$, 21.75$]
- 2024-12-30 to 2025-12-30 estimated range: [7.07$, 18.79$]
Financial Metrics affecting the ALGS estimates:
- Negative: Non-GAAP EPS, $ of -1.59 <= 0.10
- Negative: Operating profit margin, % of -84.92 <= 1.03
- Negative: Operating cash flow per share per price, % of -16.42 <= 2.35
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Net income
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Negative: Industry operating profit margin (median), % of -98.30 <= 2.14
- Positive: Interest expense per share, $ of 0 <= 0
Short-term ALGS quotes
Long-term ALGS plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $4.36MM | $13.91MM | $15.53MM |
| Operating Expenses | $132.68MM | $111.49MM | $103.66MM |
| Operating Income | $-128.32MM | $-97.58MM | $-88.13MM |
| Non-Operating Income | $0.13MM | $1.64MM | $1.24MM |
| R&D Expense | $104.15MM | $85.08MM | $73.04MM |
| Income(Loss) | $-128.19MM | $-95.94MM | $-86.88MM |
| Taxes | $0.14MM | $0.11MM | $0.80MM |
| Profit(Loss) | $-128.33MM | $-96.05MM | $-87.68MM |
| Stockholders Equity | $184.73MM | $103.90MM | $92.08MM |
| Assets | $235.37MM | $146.69MM | $151.53MM |
| Operating Cash Flow | $-115.66MM | $-79.39MM | $-79.00MM |
| Capital expenditure | $0.89MM | $0.94MM | $0.02MM |
| Investing Cash Flow | $3.02MM | $-26.29MM | $44.98MM |
| Financing Cash Flow | $78.68MM | $0.16MM | $88.33MM |
| Earnings Per Share* | $-3.22 | $-2.25 | $-3.52 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.